ImmunityBio (IBRX) Stock Forecast & Price Target

ImmunityBio reported a 21% increase in net product revenue to $7.2 million in Q4 2024, driven by accelerating sales of its IL-15 superagonist antibody-cytokine fusion protein, ANKTIVA, following FDA approval. The sustained disease-free survival rates at 18 and 24 months, recorded at 51.1% and 48.3%, respectively, highlight ANKTIVA's effectiveness and long-term benefits, which support the drug's expansion into first-line treatments for non-muscle invasive bladder cancer (NMIBC). Furthermore, projections indicate that ANKTIVA revenue could grow significantly from $137.4 million in 2025 to $4.3 billion by 2034, bolstered by factors such as a permanent reimbursement code and additional regulatory approvals in international markets.

ImmunityBio Inc has consistently reported operating losses since its inception, raising concerns about its potential for achieving profitability in the coming years. The company's existing debt and revenue interest liabilities threaten to adversely impact cash flows, thereby limiting its flexibility to secure additional capital for future operations and growth initiatives. Furthermore, challenges related to regulatory approval timelines, declining response rates for treatments, and skepticism regarding large-scale manufacturing capabilities contribute to a negative outlook on the stock's future performance.